Exhibit 99.1 www.e2open.com Press Release E2open Announces Fiscal 2025 Third Quarter Financial Results GAAP subscription revenue of $132.0 million, above midpoint of Q3 guidance range DALLAS – January 10, 2025 – E2open Parent Holdings, Inc. (NYSE: ETWO) ("e2open" or the "Company"), the connected supply chain SaaS platform with the largest multi-enterprise network, today announced financial results for its fiscal third quarter ended November 30, 2024. "During the third quarter, e2open made further progress i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14063 JABIL INC. (Exact name of registrant as specified in its charter) Delaware 38-1886260 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 INTELLIA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37766 36-4785571 (State or Other Jurisdiction of Incorporation) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) (Commissio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K 1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 (Address of principal executive offices, including zip code) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) Delaware 001-40880 87-10 ...

Rhythm Pharmaceuticals January 2025 © Rhythm® Pharmaceuticals, Inc. All rights reserved. Exhibit 99.2 Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, ar ncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of setmel (formerly LB54640), and RM718, including the anticipated timing for initiation of clinical trials ...

Exhibit 99.1 Walgreens Boots Alliance Reports Fiscal 2025 First Quarter Results Delivering Progress on Strategic Priorities; Maintaining Full Year Adjusted EPS Guidance First quarter financial results Fiscal 2025 guidance* • Maintaining fiscal 2025 adjusted EPS2 guidance of $1.40 to $1.80, with growth in U.S. Healthcare and International more than offset by a decline in U.S. Retail Pharmacy, a higher adjusted effective tax rate, and lower contributions from sale-leaseback and Cencora earnings DEERFIELD, Ill ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (919) 859-1302 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is inte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2025 ImmuCell Corporation | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | DE | 001-12934 | 01-0382980 | | (State or other jurisdiction | (Commission File Number) | (IRS Employer | | of incorporation) | | Identification No.) | | 56 Evergreen Drive P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K _____________________________________________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2025 _____________________________________________________________ D-Wave Quantum Inc. (Exact Name of Registrant as Specified in Its Charter) _____________________________________________________________ Delaware 001-4146 ...

Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025 Forward-Looking Statements This communication includes express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Littleation Reforical frances naticals oncernes include all statements that are not thistorical facts and, in same cases can be identified op terms such as may Reforio for 1995. Forw "will " "ongoing," or the negative of these ter ...